Federal contractor · LOWELL, MA

VERSATOPE THERAPEUTICS INC

No contract obligations recorded for VERSATOPE THERAPEUTICS INC in FY2026. Since FY2018: $17.2M. It also received $999.9K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
VSMPM3EGYYA6
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 450KFY2018
  2. 2.1MFY2019
  3. 3.8MFY2020
  4. 1.4MFY2021
  5. 893KFY2022
  6. 4MFY2023
  7. 3.6MFY2024
  8. 955.2KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for VERSATOPE THERAPEUTICS INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

VERSATOPE THERAPEUTICS INC received $999.9K in federal assistance in FY2026, on 1 actions (0 new awards), −0% vs FY2025. Its largest program was 93.855 · Allergy and Infectious Diseases Research ($999.9K).

Assistance · FY2026
$999.9K
New awards
0
Actions
1
Since FY2022
$3M

Assistance by fiscal year

  1. 0FY2022
  2. 999.8KFY2024
  3. 1MFY2025
  4. 999.9KFY2026

By type

  1. Grants$999.9K100%

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$999.9K100%

Awarding agencies

  1. National Institutes of Health$999.9K100%
    Department of Health and Human Services

Largest awards

  1. RECOMBINANT OUTER MEMBRANE VESICLES AS A NOVEL ADJUVANT FOR A MALARIA VACCINE - ABSTRACT WHILE VACCINES ARE AN INTEGRAL COMPONENT OF…$3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Dec 8, 2023 – Jun 11, 2026· R44AI181242

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2022–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. MEDIGEN, INC.$4.5M+5.8% in FY2026
    FREDERICK, MD · 98% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. GREATER LOS ANGELES VETERANS RESEARCH AND EDUCATION FOUNDATION$4.8M+91% in FY2026
    LOS ANGELES, CA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. AN2 THERAPEUTICS, INC$4.3M−100% in FY2026
    MENLO PARK, CA · 94% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.